Although limited by a retrospective observational design and lack of constant up-titration for LIRA to the highest dose as the active comparator, the findings of this study demonstrate that treatment of T2D with DU 1.5 mg/once weekly on a background of MET or a combination of MET plus conventional insulin secretagogues can lead to durable benefits in relation to glycometabolic control and body weight, with a favorable safety profile, especially in presence of obesity and greater HbA1c impairment. The gene discussed is INS; the disease is type 2 diabetes mellitus.